Han Yong Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Han Yong Choi has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
Hyun Moo Lee
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
12 shared publicationsByong Chang Jeong
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
7 shared publicationsSeong Il Seo
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
7 shared publications- Seong Il Seo
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
7 shared publications - Seong Soo Jeon
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
7 shared publications Seong Soo Jeon
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
6 shared publications
Latest Publications
- Open Access
- 3 May 2019
- Published by Springer Nature in BMC Urology
- Vol. 19 (1) , 30
A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
Results from randomized phase III trials have shown that thrice-weekly docetaxel added to androgen-deprivation therapy (ADT) has a significant impact on the survival of patients with metastatic castration-naïve prostate cancer (mCNPC) and established early chemotherapy as part of the standard of care for high-risk disease. Controversy remains, however, because some patients experience critical toxicities related to docetaxel. The purpose of the current study was to evaluate the feasibility and adverse events of biweekly-administered docetaxel in patients with previously-untreated, high-risk mCNPC. The study included 35 consecutive patients with high-risk mCNPC who received ADT plus docetaxel 40 mg/m2. Oral prednisone 5 mg twice daily was also given. Treatment was repeated every two weeks for up to 12 cycles or until disease progression or unacceptable toxicity occurred. High-risk was defined as bone metastases beyond axial skeleton and/or visceral disease. The included patients’ median age was 68 years (range: 31–86 years) and 17 (49%) had visceral metastases. Biweekly docetaxel was generally well-tolerated; the most commonly observed adverse events, considering those of all grades, included alopecia (74%), nail changes (42%), and constipation (31%). Hematologic adverse events were infrequent, and no patient received hematopoietic growth factors. One patient died after the fourth cycle due to respiratory failure, which occurred as a complication of pneumonia. Among the 35 patients, 28 completed the planned 12 cycles of biweekly docetaxel. Prostate-specific antigen response (> 50% decrease from baseline) was recorded in 33 patients (94%), and the radiologic response rate was 49%. Median progression-free survival was 13.6 months (95% confidence interval: 6.7–20.4). ADT plus biweekly-administered docetaxel appeared to be tolerated and effective in patients with high-risk mCNPC.
- 3 May 2019
- Published by Springer Nature in BMC Urology
- Vol. 19 (1) , 30
Open AccessA retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
Results from randomized phase III trials have shown that thrice-weekly docetaxel added to androgen-deprivation therapy (ADT) has a significant impact on the survival of patients with metastatic castration-naïve prostate cancer (mCNPC) and established early chemotherapy as part of the standard of care for high-risk disease. Controversy remains, however, because some patients experience critical toxicities related to docetaxel. The purpose of the current study was to evaluate the feasibility and adverse events of biweekly-administered docetaxel in patients with previously-untreated, high-risk mCNPC. The study included 35 consecutive patients with high-risk mCNPC who received ADT plus docetaxel 40 mg/m2. Oral prednisone 5 mg twice daily was also given. Treatment was repeated every two weeks for up to 12 cycles or until disease progression or unacceptable toxicity occurred. High-risk was defined as bone metastases beyond axial skeleton and/or visceral disease. The included patients’ median age was 68 years (range: 31–86 years) and 17 (49%) had visceral metastases. Biweekly docetaxel was generally well-tolerated; the most commonly observed adverse events, considering those of all grades, included alopecia (74%), nail changes (42%), and constipation (31%). Hematologic adverse events were infrequent, and no patient received hematopoietic growth factors. One patient died after the fourth cycle due to respiratory failure, which occurred as a complication of pneumonia. Among the 35 patients, 28 completed the planned 12 cycles of biweekly docetaxel. Prostate-specific antigen response (> 50% decrease from baseline) was recorded in 33 patients (94%), and the radiologic response rate was 49%. Median progression-free survival was 13.6 months (95% confidence interval: 6.7–20.4). ADT plus biweekly-administered docetaxel appeared to be tolerated and effective in patients with high-risk mCNPC.
- 22 January 2019
- Published by Wiley in The Prostate
- Vol. 79 (6) , 614-621
A randomized, double‐blind, placebo‐controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation
Background: The anti‐cancer activities of curcumin are well‐documented from preclinical studies using prostate cancer models. Our objective was to evaluate the anti‐cancer activity of oral curcumin in patients with prostate cancer.Methods: This randomized, double‐blind, placebo‐controlled trial was performed on patients with prostate cancer who received intermittent androgen deprivation (IAD). Participants who finished the first on‐treatment period of IAD were randomized into a curcumin or placebo group. The patients took oral curcumin (1440 mg/day) or placebo for six months and were followed up until the beginning of the second on‐treatment. The primary end‐point was duration of the first off‐treatment. The secondary end‐points were change in PSA and testosterone levels during 6 months, PSA progression rate, and health‐related quality of life (HRQOL) scores at 6 months. Safety assessments included adverse event, adverse drug reaction, and serious adverse event.Results: A total of 97 participants were randomized 1:1 to curcumin (n = 49) and placebo (n = 48) groups. Among them, 82 patients (84.5%) were evaluable for the analysis (39 and 43 patients in the curcumin and placebo groups, respectively). The median off‐treatment duration was 16.3 months (95% confidence interval [CI] 12.3‐20.3 months) and 18.5 months (95% CI 12.5‐23.0 months) in the curcumin and placebo groups, respectively. There was no significant difference in the curve of off‐treatment duration between the two groups (P = 0.4816). The proportion of patients with PSA progression during the active curcumin treatment period (6 months) was significantly lower in the curcumin group than the placebo group (10.3% vs 30.2%, P = 0.0259). The change of PSA, testosterone levels during 6 months, and HRQOL scores at 6 months were not different between curcumin and placebo groups. Adverse events were higher in the placebo group (16 of 46 vs 7 of 45 patients, P = 0.0349). No significant differences in the adverse drug reaction were found between the two groups.Conclusions: Six months’ intake of oral curcumin did not significantly affect the overall off‐treatment duration of IAD. However, PSA elevation was suppressed with curcumin intake during the curcumin administration period. Curcumin at this dose was well tolerated and safe.
- 22 January 2019
- Published by Wiley in The Prostate
- Vol. 79 (6) , 614-621
A randomized, double‐blind, placebo‐controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation
Background: The anti‐cancer activities of curcumin are well‐documented from preclinical studies using prostate cancer models. Our objective was to evaluate the anti‐cancer activity of oral curcumin in patients with prostate cancer.Methods: This randomized, double‐blind, placebo‐controlled trial was performed on patients with prostate cancer who received intermittent androgen deprivation (IAD). Participants who finished the first on‐treatment period of IAD were randomized into a curcumin or placebo group. The patients took oral curcumin (1440 mg/day) or placebo for six months and were followed up until the beginning of the second on‐treatment. The primary end‐point was duration of the first off‐treatment. The secondary end‐points were change in PSA and testosterone levels during 6 months, PSA progression rate, and health‐related quality of life (HRQOL) scores at 6 months. Safety assessments included adverse event, adverse drug reaction, and serious adverse event.Results: A total of 97 participants were randomized 1:1 to curcumin (n = 49) and placebo (n = 48) groups. Among them, 82 patients (84.5%) were evaluable for the analysis (39 and 43 patients in the curcumin and placebo groups, respectively). The median off‐treatment duration was 16.3 months (95% confidence interval [CI] 12.3‐20.3 months) and 18.5 months (95% CI 12.5‐23.0 months) in the curcumin and placebo groups, respectively. There was no significant difference in the curve of off‐treatment duration between the two groups (P = 0.4816). The proportion of patients with PSA progression during the active curcumin treatment period (6 months) was significantly lower in the curcumin group than the placebo group (10.3% vs 30.2%, P = 0.0259). The change of PSA, testosterone levels during 6 months, and HRQOL scores at 6 months were not different between curcumin and placebo groups. Adverse events were higher in the placebo group (16 of 46 vs 7 of 45 patients, P = 0.0349). No significant differences in the adverse drug reaction were found between the two groups.Conclusions: Six months’ intake of oral curcumin did not significantly affect the overall off‐treatment duration of IAD. However, PSA elevation was suppressed with curcumin intake during the curcumin administration period. Curcumin at this dose was well tolerated and safe.
- Open Access
- 29 August 2018
- Published by Wiley in Cancer Medicine
- Vol. 7 (10) , 5083-5095
Novel therapeutic roles of MC ‐4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways
Current clinical trials of new anticancer therapies against metastatic renal cell carcinoma ( RCC ), including molecular‐targeted therapies, have not shown promise. The purpose of this study was to preclinically assess the antitumor effects of MC ‐4, a partially purified material of Artemisia annua L., as a monotherapy or in combination with the known mechanistic target of rapamycin complex 1 ( mTORC 1) inhibitor, everolimus, against Caki‐1 (Von Hippel‐Lindau ( VHL )+/+) and 786‐O ( VHL −/−) human RCC cells. MC ‐4 monotherapy significantly increased tumor growth inhibition and autophagic cell death in RCC cells in vitro and in vivo . Everolimus led to compensatory Akt activation by inhibiting only mTORC 1 signaling pathway. In contrast to everolimus, MC ‐4 enhanced phosphatase and tensin homolog expression and reduced its downstream effector, Akt/pyruvate kinase muscle isozyme M2 ( PKM 2), leading to decreased expression of glucose transporter 1, which is associated with cancer cell metabolism. The synergistic antitumor and anti‐metastatic effects induced by co‐administration of MC ‐4 and everolimus involve cell growth inhibition and autophagic cell death via dual targeting of phosphatidylinositol 3‐kinase ( PI 3K)/Akt/ PKM 2 and mTORC 1. These findings suggest that MC ‐4 is a novel Akt/ PKM 2 inhibitor that can overcome the limitation of existing mTOR inhibitors and can be considered a novel strategy to treat patients with rapidly progressing advanced RCC.
- 29 August 2018
- Published by Wiley in Cancer Medicine
- Vol. 7 (10) , 5083-5095
Open AccessNovel therapeutic roles of MC ‐4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways
Current clinical trials of new anticancer therapies against metastatic renal cell carcinoma ( RCC ), including molecular‐targeted therapies, have not shown promise. The purpose of this study was to preclinically assess the antitumor effects of MC ‐4, a partially purified material of Artemisia annua L., as a monotherapy or in combination with the known mechanistic target of rapamycin complex 1 ( mTORC 1) inhibitor, everolimus, against Caki‐1 (Von Hippel‐Lindau ( VHL )+/+) and 786‐O ( VHL −/−) human RCC cells. MC ‐4 monotherapy significantly increased tumor growth inhibition and autophagic cell death in RCC cells in vitro and in vivo . Everolimus led to compensatory Akt activation by inhibiting only mTORC 1 signaling pathway. In contrast to everolimus, MC ‐4 enhanced phosphatase and tensin homolog expression and reduced its downstream effector, Akt/pyruvate kinase muscle isozyme M2 ( PKM 2), leading to decreased expression of glucose transporter 1, which is associated with cancer cell metabolism. The synergistic antitumor and anti‐metastatic effects induced by co‐administration of MC ‐4 and everolimus involve cell growth inhibition and autophagic cell death via dual targeting of phosphatidylinositol 3‐kinase ( PI 3K)/Akt/ PKM 2 and mTORC 1. These findings suggest that MC ‐4 is a novel Akt/ PKM 2 inhibitor that can overcome the limitation of existing mTOR inhibitors and can be considered a novel strategy to treat patients with rapidly progressing advanced RCC.
- 1 August 2017
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 15 (4) , e645-e652
Comparison of Oncologic Outcomes and Complications According to Surgical Approach to Radical Prostatectomy: Special Focus on the Perineal Approach
- 1 August 2017
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 15 (4) , e645-e652
Comparison of Oncologic Outcomes and Complications According to Surgical Approach to Radical Prostatectomy: Special Focus on the Perineal Approach
- 1 June 2017
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 15 (3) , e379-e385
De Ritis Ratio (AST/ALT) as a Significant Prognostic Factor in Patients With Upper Tract Urothelial Cancer Treated With Surgery
- 1 June 2017
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 15 (3) , e379-e385
De Ritis Ratio (AST/ALT) as a Significant Prognostic Factor in Patients With Upper Tract Urothelial Cancer Treated With Surgery
- Open Access
- 31 December 2016
- Published by Korean Urological Oncology Society in The Korean Journal of Urological Oncology
- Vol. 14 (3) , 144-151
Twenty-Year Single Surgeon Experience with Radical Perineal Prostatectomy: Oncologic, Functional Outcomes and Perioperative Complications
To evaluate oncologic, functional outcomes and complications in patients with prostate cancer (PCa) who underwent radical perineal prostatectomy (RPP). Materials and Methods: A retrospective review of patients who underwent RPP by a single surgeon between 1995 and 2014 was performed. We analyze clinicopathologic characteristics and postoperative complications including urinary continence and erectile function. Kaplan-Meier survival analysis was used to access biochemical recurrence (BCR)-free survival (BFS) and cancer-specific survival (CSS) and log-rank test was applied. Complications were stratified by the Clavien-Dindo classification system. Results: A total of 816 patients were included in this study. The mean prostate-specific antigen and prostate volume was 8.89 ng/mL and 30.8 mL. Positive surgical margin was identified in 174 patients (21.3%) after RPP. During a mean follow-up of 58.7 months, 173 patients (21.2%) experienced BCR. Overall, 44 patients (5.4%) died, of which 15 (1.8%) died from PCa. The 5-year BFS in patients with T2, T3a, and T3b were 84.8%, 69.7%, and 46.7% (p<0.001), respectively. The 10-year CSS in patients with same groups were 98.9%, 98.2%, and 79.5% (p<0.001), respectively. At 12 months after RPP, recovery of urinary continence and erectile function was identified in 88.3% and 63.7% of patients. Wound dehiscence (8.9%) was the most common complication. However, approximately 78% of complications were grade I or II. Conclusions: Our study indicates that RPP shows acceptable outcomes in terms of oncologic results and complications in patients with PCa. Careful attention is required to prevent wound dehiscence. (Korean J Urol Oncol 2016;14:144-151)
- 31 December 2016
- Published by Korean Urological Oncology Society in The Korean Journal of Urological Oncology
- Vol. 14 (3) , 144-151
Open AccessTwenty-Year Single Surgeon Experience with Radical Perineal Prostatectomy: Oncologic, Functional Outcomes and Perioperative Complications
To evaluate oncologic, functional outcomes and complications in patients with prostate cancer (PCa) who underwent radical perineal prostatectomy (RPP). Materials and Methods: A retrospective review of patients who underwent RPP by a single surgeon between 1995 and 2014 was performed. We analyze clinicopathologic characteristics and postoperative complications including urinary continence and erectile function. Kaplan-Meier survival analysis was used to access biochemical recurrence (BCR)-free survival (BFS) and cancer-specific survival (CSS) and log-rank test was applied. Complications were stratified by the Clavien-Dindo classification system. Results: A total of 816 patients were included in this study. The mean prostate-specific antigen and prostate volume was 8.89 ng/mL and 30.8 mL. Positive surgical margin was identified in 174 patients (21.3%) after RPP. During a mean follow-up of 58.7 months, 173 patients (21.2%) experienced BCR. Overall, 44 patients (5.4%) died, of which 15 (1.8%) died from PCa. The 5-year BFS in patients with T2, T3a, and T3b were 84.8%, 69.7%, and 46.7% (p<0.001), respectively. The 10-year CSS in patients with same groups were 98.9%, 98.2%, and 79.5% (p<0.001), respectively. At 12 months after RPP, recovery of urinary continence and erectile function was identified in 88.3% and 63.7% of patients. Wound dehiscence (8.9%) was the most common complication. However, approximately 78% of complications were grade I or II. Conclusions: Our study indicates that RPP shows acceptable outcomes in terms of oncologic results and complications in patients with PCa. Careful attention is required to prevent wound dehiscence. (Korean J Urol Oncol 2016;14:144-151)
- Open Access
- 1 January 2016
- Published by XMLink in Journal of Korean Medical Science
- Vol. 31 (12) , 1983-1988
A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma
Kim SH, et al. J Korean Med Sci. 2016 Dec;31(12):1983-1988. https://doi.org/10.3346/jkms.2016.31.12.1983
- 1 January 2016
- Published by XMLink in Journal of Korean Medical Science
- Vol. 31 (12) , 1983-1988
Open AccessA Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma
Kim SH, et al. J Korean Med Sci. 2016 Dec;31(12):1983-1988. https://doi.org/10.3346/jkms.2016.31.12.1983
- Open Access
- 28 September 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (32) , 33046-33064
Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis
Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis
- 28 September 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (32) , 33046-33064
Open AccessRepurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis
Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis
- Open Access
- 25 February 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (3) , 4471-4491
Tumor Progression Locus 2 (Tpl2) Kinase as a Novel Therapeutic Target for Cancer: Double-Sided Effects of Tpl2 on Cancer
Tumor progression locus 2 (Tpl2) is a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) that conveys various intra- and extra-cellular stimuli to effector proteins of cells provoking adequate adoptive responses. Recent studies have elucidated that Tpl2 is an indispensable signal transducer as an MAP3K family member in diverse signaling pathways that regulate cell proliferation, survival, and death. Since tumorigenesis results from dysregulation of cellular proliferation, differentiation, and apoptosis, Tpl2 participates in many decisive molecular processes of tumor development and progression. Moreover, Tpl2 is closely associated with cytokine release of inflammatory cells, which has crucial effects on not only tumor cells but also tumor microenvironments. These critical roles of Tpl2 in human cancers make it an attractive anti-cancer therapeutic target. However, Tpl2 contradictorily works as a tumor suppressor in some cancers. The double-sided effects of Tpl2 originate from the specific upstream and downstream signaling environment of each tumor, since Tpl2 interacts with various signaling components. This review summarizes recent studies concerning the possible roles of Tpl2 in human cancers and considers its possibility as a therapeutic target, against which novel anti-cancer agents could be developed.
- 25 February 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (3) , 4471-4491
Open AccessTumor Progression Locus 2 (Tpl2) Kinase as a Novel Therapeutic Target for Cancer: Double-Sided Effects of Tpl2 on Cancer
Tumor progression locus 2 (Tpl2) is a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) that conveys various intra- and extra-cellular stimuli to effector proteins of cells provoking adequate adoptive responses. Recent studies have elucidated that Tpl2 is an indispensable signal transducer as an MAP3K family member in diverse signaling pathways that regulate cell proliferation, survival, and death. Since tumorigenesis results from dysregulation of cellular proliferation, differentiation, and apoptosis, Tpl2 participates in many decisive molecular processes of tumor development and progression. Moreover, Tpl2 is closely associated with cytokine release of inflammatory cells, which has crucial effects on not only tumor cells but also tumor microenvironments. These critical roles of Tpl2 in human cancers make it an attractive anti-cancer therapeutic target. However, Tpl2 contradictorily works as a tumor suppressor in some cancers. The double-sided effects of Tpl2 originate from the specific upstream and downstream signaling environment of each tumor, since Tpl2 interacts with various signaling components. This review summarizes recent studies concerning the possible roles of Tpl2 in human cancers and considers its possibility as a therapeutic target, against which novel anti-cancer agents could be developed.
- Open Access
- 1 January 2015
- Published by XMLink in Journal of Korean Medical Science
- Vol. 30 (11) , 1631-1637
Is Radical Perineal Prostatectomy a Viable Therapeutic Option for Intermediate- and High-risk Prostate Cancer?
Lee HW, et al. J Korean Med Sci. 2015 Nov;30(11):1631-1637. http://dx.doi.org/10.3346/jkms.2015.30.11.1631
- 1 January 2015
- Published by XMLink in Journal of Korean Medical Science
- Vol. 30 (11) , 1631-1637
Open AccessIs Radical Perineal Prostatectomy a Viable Therapeutic Option for Intermediate- and High-risk Prostate Cancer?
Lee HW, et al. J Korean Med Sci. 2015 Nov;30(11):1631-1637. http://dx.doi.org/10.3346/jkms.2015.30.11.1631